Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 11/20 | 0.51 |
| ▸ | GRM5 | P41594 | 11/20 | 0.51 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.46 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | EED | O75530 | 1/20 | 0.45 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.45 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.45 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.45 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.45 |
| ▸ | CDK9 | P50750 | 1/20 | 0.45 |
| ▸ | FAAH | O00519 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxazole SCHEMBL6241338 | 0.92 | GRM1 (0.47) | GRM1GRM5PDK4GPR119TNK2 | |
| SCHEMBL31169299 | 0.88 | GRM1 (0.48) | GRM1GRM5PDK4GPR119NAMPT | |
| SCHEMBL20028660 | 0.81 | FAAH (0.45) | GRM5GPR119FAAH | |
| SCHEMBL7470566 | 0.80 | GRM5 (0.60) | GRM1GRM5PDK4GPR119TNK2 | |
| SCHEMBL15024195 | 0.78 | GRM1 (0.60) | GRM1GRM5PDK4TNK2NAMPT | |
| SCHEMBL15756313 | 0.78 | GRM1 (0.52) | GRM1GRM5PDK4GPR119NAMPT | |
| SCHEMBL7941280 | 0.78 | GRM1 (0.49) | GRM1GRM5PDK4GPR119TNK2 | |
| SCHEMBL1863518 | 0.77 | GRM1 (0.67) | GRM1GRM5PDK4GPR119NAMPT | |
| SCHEMBL15785120 | 0.77 | PDK4 (0.56) | GRM1GRM5PDK4GPR119NAMPT | |
| SCHEMBL31227073 | 0.76 | WNT3A (0.61) | GRM1GRM5PDK4GPR119TNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7528134-B2 | Acetamides and benzamides that are useful in treating sexual dysfunction | ABBOTT LABORATORIES INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-20060009461-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | BHATIA PRAMILA A | 2006-01-12 | — | — | US | disclosed |
| US-20040029887-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2004-02-12 | — | — | US | disclosed |
| US-20030229094-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2003-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229094-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | CATSPER1, CYP19A1, PDE12 | GRM1 1437/4885GRM5 1577/4885PDK4 2086/4885 |
| US-20040029887-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | CATSPER1, CYP19A1, PDE12 | GRM1 1437/4885GRM5 1577/4885PDK4 2086/4885 |
| US-20060009461-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | PDE12, NAAA, CYP19A1 | GRM1 2533/4885GRM5 1310/4885PDK4 1710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.